The proposed Placing announced this morning, to raise £19.3m, represents an important inflection point for Realm. Both of the company’s lead programmes (PR022 in atopic dermatitis and PR013 in allergic conjunctivitis) are due to enter Phase II by the end of 2017, with data expected in mid-2018. Although the initial Phase II trials are fully funded through to completion by existing cash resources ($15.56m at period-end), the additional capital from the Placing will provide greater flexibility fol ....
22 Sep 2017
N+1 Singer - Realm Therapeutics - H1 results and proposed £19m equity fundraise
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Realm Therapeutics - H1 results and proposed £19m equity fundraise
Realm Therapeutics (RLM:LON) | 0 0 0.3% | Mkt Cap: 57.1m
- Published:
22 Sep 2017 -
Author:
Dr Jens Lindqvist -
Pages:
3
The proposed Placing announced this morning, to raise £19.3m, represents an important inflection point for Realm. Both of the company’s lead programmes (PR022 in atopic dermatitis and PR013 in allergic conjunctivitis) are due to enter Phase II by the end of 2017, with data expected in mid-2018. Although the initial Phase II trials are fully funded through to completion by existing cash resources ($15.56m at period-end), the additional capital from the Placing will provide greater flexibility fol ....